Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2019-01-30Clinical Trial Update: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients [Phase 2]
A Phase 2 trial evaluating repeated dosing of a high-dose influenza vaccine in patients with gammopathy (including multiple myeloma and rela…
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 results from a study using donor umbilical cord blood stem cell transplants in patients with hematologic malignancies have been post…
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 [Phase 2]
Phase 2 trial investigating obinutuzumab induction in relapsed/refractory Waldenström macroglobulinemia (OBI-1).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors [Phase 1]
This clinical trial update reports the completion of a Phase 1 study of CB-839 (telaglenastat), a glutaminase inhibitor, in hematological tu…
-
CLINICAL_TRIALS trial_result · 2018-07-02Clinical Trial Update: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating a triple regimen of devimistat (CPI-613), bendamustine hydrochloride, and rituximab in relapsed or refractory B-cel…
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results …
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF [Phase 1]
Phase 1 study evaluating mobilization of autologous peripheral blood stem cells using interleukin-2 and GM-CSF; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]
Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who…
-
CLINICAL_TRIALS trial_result · 2018-04-11Clinical Trial Update: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma [Phase 1]
Phase 1 study evaluating alisertib in combination with vorinostat in adults with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2018-03-15Clinical Trial Update: A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia [Phase 2]
This is a Phase II clinical trial update for perifosine in relapsed/refractory Waldenström's macroglobulinemia. The trial status is complete…
-
CLINICAL_TRIALS trial_result · 2018-01-26Clinical Trial Update: Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) [Phase 2]
Phase 2 trial evaluating the combination of bortezomib and rituximab in Waldenström's macroglobulinemia has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 [Phase 1, Phase 2]
Extension study update for IMO-8400 in Waldenström's macroglobulinemia following completing a prior study; results posted in 2017.
-
CLINICAL_TRIALS research · 2017-11-07Clinical Trial Update: Study of VTD in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial investigating the VTD regimen (bortezomib, thalidomide, dexamethasone) for Waldenström's macroglobulinemia and lympho…
-
CLINICAL_TRIALS trial_result · 2017-07-24Clinical Trial Update: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
This clinical trial update reports Phase 1/Phase 2 results for fludarabine and cyclophosphamide as conditioning therapy for donor stem cell …
-
CLINICAL_TRIALS research · 2017-07-19Clinical Trial Update: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/Phase 2 study of CT-1530 in relapsed or refractory B-cell non-Hodgkin lymphoma, chronic lymphocyt…
-
CLINICAL_TRIALS trial_result · 2017-06-02Clinical Trial Update: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma [Phase 1, Phase 2]
Clinical trial update reports completed Phase 1 and Phase 2 results for flavopiridol in previously treated chronic lymphocytic leukemia and …
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]
A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating thalidomide, lenalidomide, and rituximab for previously treated Waldenström macroglobulinemia was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial update for carfilzomib, rituximab and dexamethasone in Waldenström's macroglobulinemia has completed and results posted.
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia [Phase 2]
Phase 2 study of idelalisib in Waldenström macroglobulinemia was terminated, with results posted.